LEADS BIOLABS-B(09887): LBL-034(GPRC5D/CD3 bispecific T-CELL ENGAGERTCE) is granted Fast Track designation by the U.S. FDA.
Weidi Zhibo-B (09887) announced on January 27, 2026 that LBL-034 (GPRC5D/CD3 bispecific antibody) has been granted Fast Track Designation ("FTD") by the U.S. Food and Drug Administration ("FDA") for the treatment of relapsed/refractory multiple myeloma ("RRMM").
LEADS BIOLABS-B(09887) announced that on January 27, 2026, LBL-034 (GPRC5D/CD3 bispecific antibody) was granted Fast Track Designation (FTD) by the Food and Drug Administration ("FDA") in the United States for the treatment of relapsed/refractory multiple myeloma ("RRMM").
Related Articles
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Hims & Hers Health (HIMS.US) launches cheap weight loss pills, FDA stops sales the next day, stock price plummets after hours.
HK Bull/Bear Outstanding Qty Ratio(76:24) | February 7th
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Hims & Hers Health (HIMS.US) launches cheap weight loss pills, FDA stops sales the next day, stock price plummets after hours.
HK Bull/Bear Outstanding Qty Ratio(76:24) | February 7th
